IP Library Granted Patent US 7,736,858
Granted Patent B2
US 7,736,858 · App. 10/656,034 · Granted Jun 15, 2010

Method for distinguishing ulcerative colitis from Crohn's disease by detecting the presence of fecal anit-neutrophil cytoplasmic antibodies (ANCA)

Assignee: Techlab, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,736,858
App. No.
10/656,034
Granted
Jun 15, 2010
Kind
B2
Abstract

A method and apparatus for the differentiation of ulcerative colitis from Crohn's disease and other gastrointestinal illnesses using the presence of anti-neutrophil cytoplasmic antibodies (ANCA) as a marker of ulcerative colitis is described. The apparatus consists of either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobulins for the measurement of total endogenous ANCA in a human sample. The method and apparatus can be used by healthcare providers to distinguish ulcerative colitis from Crohn's disease and other gastrointestinal illnesses.

Claims (21)

1. A method for diagnosing ulcerative colitis by testing a fecal sample for an elevated level of anti-neutrophil cytoplasmic antibodies, the method comprising:

obtaining a fecal sample from a person presenting with inflammatory bowel disease;

determining whether there is an elevated level of anti-neutrophil cytoplasmic antibodies in the sample compared to an anti-neutrophil cytoplasmic antibody level in a healthy sample, wherein an elevated level of anti-neutrophil cytoplasmic antibodies is indicative of ulcerative colitis; and

diagnosing the person with anti-neutrophil cytoplasmic antibodies present in the fecal sample with ulcerative colitis.

2. The method as recited in claim 1 , further comprising:

diluting the fecal sample.

3. The method as recited in claim 2 , further comprising:

contacting the fecal sample with neutrophil cytoplasmic antigens to create a treated sample.

4. The method as recited in claim 3 , further comprising:

contacting the treated sample with polyvalent antibodies to human immunoglobulin to create a readable sample.

5. The method as recited in claim 4 , further comprising:

determining an optical density of the readable sample at 450 nm, wherein the optical density corresponds to a level of anti-neutrophil cytoplasmic antibodies in the sample.

6. A diagnostic assay for diagnosing ulcerative colitis by determining whether a fecal sample contains an elevated level of anti-neutrophil cytoplasmic antibodies, the assay comprising:

obtaining a human fecal sample from a person presenting with inflammatory bowel disease;

diluting the fecal sample;

contacting the diluted sample with neutrophil cytoplasmic antigens to create a treated sample;

contacting the treated sample with polyvalent antibodies to human immunoglobulin to create a readable sample;

determining the optical density of the readable sample at 450 nm; and

determining whether the optical density indicates an elevated level of anti-neutrophil cytoplasmic antibodies compared to an anti-neutrophil cytoplasmic antibody level in a healthy sample, where an elevated level of anti-neutrophil cytoplasmic antibodies is an indicator of ulcerative colitis.

7. The diagnostic assay as recited in claim 6 , wherein the anti-neutrophil cytoplasmic antibodies are one of IgG, IgE, IgM, IgD, IgA sec , IgA, and combinations thereof.

8. The diagnostic assay as recited in claim 6 , wherein the assay is selected from a group consisting of an enzyme-linked immunoassay and a lateral flow membrane test.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Aug 19, 2022
From: LBC CREDIT AGENCY SERVICES, LLC, AS AGENT
To: TECHLAB, INC.
Reel/Frame 061234/0473 →
SECURITY INTEREST Recorded Jul 31, 2020
From: TECHLAB, INC.
To: LBC CREDIT AGENCY SERVICES, LLC, AS AGENT
Reel/Frame 053372/0502 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2020
From: ELM PARK CAPITAL MANAGEMENT, LLC, AS AGENT
To: TECHLAB, INC.
Reel/Frame 053373/0908 →
SECURITY INTEREST Recorded Sep 16, 2016
From: TECHLAB, INC.
To: ELM PARK CAPITAL MANAGEMENT, LLC, AS AGENT
Reel/Frame 040055/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2004
From: BOONE, JAMES; LYERLY, DAVID; WILKINS, TRACY
To: TECHLAB, INC
Reel/Frame 014940/0194 →
Continuity (2)
Provisional Application 6040880900 · Sep 5, 2002
Related Publication 20040126898A1 · Jul 1, 2004